Neuroinflammation Target ID

About Curadev

Curadev is a private, clinical-stage biotechnology company founded in 2015, advancing a pipeline of novel small molecule drugs. Its lead asset, CRD3874-SI, is a first-in-class allosteric STING agonist in Phase 1 trials via a collaboration with Memorial Sloan Kettering Cancer Center. The company also has preclinical programs targeting STING antagonism, TNIK, and CLK/DYRK, supported by a leadership team with deep, long-standing relationships in drug discovery.

Therapeutic Areas